Key Developments: Transition Therapeutics Inc (TTHI.OQ)

TTHI.OQ on NASDAQ Stock Exchange Global Market

6.87USD
24 Dec 2014
Price Change (% chg)

$0.06 (+0.88%)
Prev Close
$6.81
Open
$6.83
Day's High
$6.89
Day's Low
$6.75
Volume
1,524
Avg. Vol
9,589
52-wk High
$8.18
52-wk Low
$4.36

Search Stocks

Latest Key Developments (Source: Significant Developments)

Transition Therapeutics Inc announces results from ELND005 clinical study in adults with Down Syndrome
Thursday, 20 Nov 2014 06:01am EST 

Transition Therapeutics Inc:Announced the results of a clinical study of neuropsychiatric drug candidate ELND005 in young adults with Down syndrome.Transition's wholly-owned subsidiary, Transition Therapeutics Ireland Limited (TTIL) completed this first study in Down syndrome subjects without dementia to allow optimal dose selection for future larger studies.Says the study enrolled 23 Down syndrome subjects in three study arms over a four-week treatment period: placebo (n=6), 250mg once daily (QD) (n=5), and 250mg twice daily (BID) (n=12).Says ELND005, at the doses evaluated, was determined to have an acceptable safety and tolerability profile and there were no serious adverse events reported in the study.Says the treatment emergent adverse events were reported in seven of the subjects receiving ELND005 and all were deemed to be mild in severity.Says the two ELND005 doses achieved the plasma levels expected in pharmacokinetic modeling and will inform the selection of a higher dose in a future clinical study.  Full Article

Transition Therapeutics Inc announces closing of private placement equity financing
Monday, 23 Jun 2014 06:01am EDT 

Transition Therapeutics Inc:Has closed private placement through which 3,195,487 units of company were purchased by Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders.Gross proceeds of private placement totalled $17 mln.Each unit consists of one common share, and 0.61 of common share purchase warrant with purchase price of $7.10 per whole warrant.  Full Article

Transition Therapeutics Inc enters into a private placement with investors to receive up to $30.8 mln in equity financing
Friday, 6 Jun 2014 09:01am EDT 

Transition Therapeutics Inc:Says Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders will make an investment of up to $30.8 mln.Says by purchasing 3,195,487 units of the company at a price of $5.32 per unit.Each unit consists of one common share, and 0.61 of a common share purchase warrant with a purchase price of $7.10 per whole warrant.Each whole warrant will entitle the holder, within two years from closing, to purchase one additional common share in the capital of the Company.If and when all of the warrants are exercised, the Company will realize an additional $13.8 mln, bringing the total investment to $30.8 mln before transaction costs.Closing of the private placement is expected to occur on or about June 20 and is subject to approval from the Toronto Stock Exchange.  Full Article

Transition Therapeutics Inc Announces Closing Of Private Placement Equity Financing
Thursday, 15 Aug 2013 04:36pm EDT 

Transition Therapeutics Inc announced that it has closed its previously announced private placement through which 2,625,300 units of the Company were purchased by Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders. Gross proceeds of the private placement totalled $11 million. As previously announced, each unit consists of (i) one common share, (ii) 0.325 Common Share purchase warrant with a purchase price of $4.60 per whole warrant and (iii) 0.4 Common Share purchase warrant with a purchase price of $6.50 per whole warrant. Each whole warrant will entitle the holder, within two years, to purchase one additional common share in the capital of the Company. If and when all of the warrants are exercised, the Company will realize an additional $10.7 million in proceeds.  Full Article

Transition Therapeutics Inc Enters Into Private Placement With Investors To Receive Up To USD21.7 Million In Equity Financing
Friday, 2 Aug 2013 08:01am EDT 

Transition Therapeutics Inc. announced that Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders will make an investment of up to USD21 million by purchasing 2,625,298 units of the Company at a price of USD4.19 per common share.  Full Article

Transition Therapeutics Inc Enters Into Osteoarthritis License And Collaboration Agreement With Eli Lilly And Co
Tuesday, 23 Jul 2013 04:44pm EDT 

Transition Therapeutics Inc announced the exclusive licensing of worldwide rights to a small molecule transcriptional regulator (TT-601) from Eli Lilly and Company for the treatment of osteoarthritis (OA) pain. TT-601 is a potent and selective ligand for a nuclear receptor target. Modulating the activity of this target in patients with osteoarthritis may provide pain relief to a segment of OA patients who do not have adequate response to therapy with NSAIDs (non-steroidal anti-inflammatory drugs). TT-601 has completed preclinical development to date and Transition anticipates can enter the clinic in the first half of 2014. Under the terms of the agreement, Transition has acquired the rights to develop and potentially commercialize TT-601. Lilly retains an option to reacquire all rights to TT-601 following review of clinical proof-of-concept study results. If Lilly exercises this option right, Transition would be eligible to receive payments of approximately USD130 million and a high single-digit royalty on sales of products containing TT-601 should such products be successfully commercialized. If Lilly does not exercise this option right, Lilly would be eligible for a low single-digit royalty from Transition on sales of products containing TT-601 should such products be successfully commercialized.  Full Article

Transition Therapeutics Inc Announces Exercise Of TT-401 Rights By Eli Lilly and Company
Monday, 17 Jun 2013 06:01am EDT 

Transition Therapeutics Inc announced that Eli Lilly and Company (Lilly) has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401. In conjunction with this assumption of rights, Transition will receive a USD7 million milestone payment. Lilly and Transition have amended their agreement to address future development of TT-401 and associated financial arrangements. Lilly will assume all costs and perform all future development and commercialization activities of TT-401. Transition will contribute payment of US$14 million to Lilly in three separate installments during the Phase 2 clinical study. If TT-401 is successfully commercialized, Transition will be eligible to receive approximately USD240 million in additional milestone payments. Transition will also be eligible to receive a double-digit royalty on sales of TT-401 products and a low single digit royalty on related compounds. TT-401 is a dual agonist of the GLP-1 (Glucagon-Like Peptide-1) and glucagon receptors which is being developed to treat type 2 diabetes and accompanying obesity. In March 2010, Transition entered into a licensing and collaboration agreement with Eli Lilly and Company, where Transition acquired the rights to a series of pre-clinical compounds from Lilly, including TT-401 for the treatment of type 2 diabetes.  Full Article

Transition Therapeutics Inc Announces Results Of Clinical Study Of Type 2 Diabetes Drug Candidate TT-401
Tuesday, 30 Apr 2013 06:01am EDT 

Transition Therapeutics Inc announced results of a five-week proof of concept clinical study of TT-401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT-401 a once-weekly administered peptide, demonstrated improvements in glycemic control and reductions in body weight. The study enrolled diabetic patients at five dosing levels and non-diabetic obese patients at one dose level. All dosing cohorts received five doses over a five week period. Diabetic patients were on stable doses of metformin. At the end of the treatment period, TT-401-treated patients in the three highest dose groups experienced statistically reductions in mean fasting plasma glucose relative to placebo. Statistically mean body weight reduction relative to baseline occurred in the three highest dose groups. A similar reduction in body weight was also observed in the obese non-diabetic cohort.  Full Article

Search Stocks